(2015; 11 pages)
The WHO Good Governance for Medicines (GGM) programme was launched in 2004 with the goal of contributing to health systems strengthening and preventing corruption by promoting good governance in the pharmaceutical sector. Its objectives are to: raise awareness on the impact of corruption in the pharmaceutical sector and bring this to the national health policy agenda; increase transparency and accountability in medicine regulatory and supply management systems; promote individual and institutional integrity in the pharmaceutical sector; and institutionalize good governance in pharmaceutical systems by building national capacity and leadership. The concept underlying the GGM approach is that by supporting policy-makers and national officials to understand where the strengths and weaknesses lie in national pharmaceutical systems, appropriate interventions can be developed and applied.
The GGM programme is implemented through a three phase process, starting with a national transparency assessment, followed by the development of a national programme for promoting good governance and then by its implementation. This process is meant to provide countries with a flexible road map to implementing the national GGM programme. It is action oriented, concrete and measurable. The process assists to institutionalize the GGM programme in national structures. Phases I and II set the foundation for the implementation of Phase III, which is considered the most critical step of the process. While Phase I provides a baseline for initiating the GGM work and evidence for policy-/decision-makers to help them prioritize and direct resources to those areas found most vulnerable, Phase II is a nationwide consultation process for developing and agreeing on a national GGM framework. The intercountry meeting on Good Governance for Medicines for Phase I countries in the Eastern Mediterranean Region was held in Jordan, Amman, from 16 to 19 August 2015. The meeting involved representatives from anti-corruption agencies, independent national assessors and government counterparts from six target countries including Afghanistan, Iraq, Jordan, Lebanon, Morocco and Pakistan (Libya and Yemen could not participate).